Saturday, October 12, 2024
Advertisement
  1. You Are At:
  2. News
  3. India
  4. Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

Biological E, Bharat Biotech have stockpile of 250 million COVID vaccine doses

It is good news that India has 250 million doses of COVID-19 vaccines ready to dispatch as the threat of Covid spread is looming large.

Edited By: Raju Kumar @rajudelhi123 New Delhi Published on: December 28, 2022 13:23 IST
250 million doses are ready
Image Source : PTI/REPRESENTATIVE 250 million doses are ready

As Covid cases are increasing in the country, now focus is back on vaccination drive. According to sources- two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together have about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.

Corbevax and Covaxin stocks

Biological E held 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech kept stockpile of 50 million doses of Covaxin.

Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government.

In March ’22, Biological E successfully supplied 10 crore doses to the government.

"Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Paradkar told PTI.

The vaccine has been developed by Biological E in collaboration with Texas Children’s Hospital Center for Vaccine Development (Texas Children's CVD) and Baylor College of Medicine (Baylor) in Houston, Texas, USA.

He further said Biological E can begin with the additional vaccine supplies within eight weeks of future orders and can manufacture and supply approximately 10 crore doses of Corbevax on a monthly basis as per its qualified manufacturing capacity.

Bharat Biotech sources said the vaccine maker has more than 50 million doses of Covaxin readily available in vials, and over 200 million doses as drug substance.

"Additional production capacity is also available to meet product demand," they said adding fresh stocks of the vaccine are available and ready for supplies.

Covaxin, India's indigenous COVID-19 vaccine, was developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).

Due to lack of product demand, production stoppage of Covaxin was initiated earlier this year and also the 50 million doses in vials are set to expire during early 2023, resulting in losses to the company, sources had earlier said.

Also Read: COVID-19 update: India reports 188 fresh cases in last 24 hours, active tally rises to 3,468

 

Advertisement

Read all the Breaking News Live on indiatvnews.com and Get Latest English News & Updates from India

Advertisement
Advertisement
Advertisement
Advertisement